Sign up online today & collaborate
or click here to find out more
Harwell, Oxford, UK – The Electrospinning Company has appointed two new non-executive members to its Board of Directors to help develop its strategy and drive its growing business in the regenerative medical device sector. Drummond Paris and Nigel Edwards join Kate Ronayne (STFC Innovations), Malcolm Chapman (lead angel investor) and Ann Kramer (CEO) as well as observer Mark White (Rainbow Seed Fund).
Drummond Paris is appointed as chairperson. After early experience in pharmaceutical sales, marketing and clinical research, he was appointed to a number of increasingly senior management positions in the Pharmaceutical Industry with Sandoz and Novartis. More recently, in non-executive chairmanship roles, he led the Board of early stage, medical technology company, Sirigen, in building an attractive medical technology business which was acquired in by Becton Dickinson. He was also chairman of start-up pharma company, Karus Therapeutics, over a 7 year period, during which time he supported the business in raising sufficient funds to develop 2 unique classes of small molecule cancer therapies. He stepped down from this role in 2014 after the Company successfully received the second tranche of £20 million series B investment from a syndicate of three major life- science VCs.
Nigel Edwards has over 30 years’ industry experience in commercial development, strategic planning, M&A and IP gained across Medtech, Biotech and Pharma in roles for Biocompatibles, Metris Therapeutics, Eli Lilly and GSK/Wellcome. He set up and leads the consultancy Medicon Strategic Development Ltd. which provides commercialisation, corporate transactions and IP advice. He holds an MBA from Cranfield Business School.
|Company||The Electrospinning Company|